The detection of specific antibodies reacting with lipids in myelin, the main target in MS, has been troublesome due to technical issues and antibody parameters in serum samples of MS patients. To this end, the current study aimed to develop a high-sensitive technique to detect antibodies to lipids in MS patients. Furthermore, IgM and IgG antibodies in reaction with PC or lactosylceramide (LC) were assessed as potential biomarkers in these patients. The team collected serum samples of 362 MS patients (clinically isolated syndrome, n=17; primary progressive MS, n=37; relapsing-remitting MS, n=62; secondary progressive MS, n=50; benign MS, n=36), 80 control participants, and 10 patients with non-MS myelin diseases. Prof Maria Cruz Sádaba (Private University San Pablo CEU, Spain) presented the results.
The novel, ultra-sensitive ELISA assay, developed by the researchers, was able to significantly differentiate between the serum levels of IgM-PC in MS patients (optical density (OD) mean 0.192) and control subjects (OD mean 0.078; P=0.001) [2]. Furthermore, the tool was able to distinguish between patients with clinically isolated syndrome (OD mean 0.281; P=0.035) and relapsing-remitting MS (OD mean 0.244; P=0.011) on the one hand, and patients with progressive forms of the disease on the other hand (primary progressive OD mean 0.170; secondary progressive OD mean 0.200). Progressive forms of MS could be differentiated from benign MS based on IgM-PC serum concentration. An additional analysis confirmed these results: a higher proportion of patients with clinically isolated syndrome displayed IgM-PC in serum samples (88.2%), compared with patients with secondary progressive MS (58.0%; P=0.037), primary progressive MS (59.5%; P=0.034), benign MS (11.1%; P=0.0001), control participants (25.0%; P=0.0001), and non-MS myelin disease (30.0%; P=0.004). In patients with relapsing-remitting MS, 88.7% showed IgM-PC in serum samples, significantly more than patients with benign MS, progressive forms of MS, and healthy controls, respectively. IgG-PC, IgG-LC, and IgM-LC levels did not differ between MS patients and controls.
- Sádaba MC, et al. Detection of IgM to phosphatidylcholine in serum samples is a major diagnosis marker in MS. P003, ECTRIMS 2021 Virtual Congress, 13–15 October.
- Sádaba MC, et al. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e765.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Cortical lesions predict cognitive impairment 20 years after MS diagnosis Next Article
Early predictors of disability progression in paediatric-onset MS »
« Cortical lesions predict cognitive impairment 20 years after MS diagnosis Next Article
Early predictors of disability progression in paediatric-onset MS »
Table of Contents: ECTRIMS 2021
Featured articles
Preliminary data shows positive results of ATA188 for progressive MS
COVID-19
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Experimental Treatments
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
Treatment Trials and Strategies
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
Biomarkers
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
Imaging
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Eculizumab, satralizumab, or inebilizumab for NMOSD?
Long-term efficacy of satralizumab for NMOSD
Long-term efficacy data: inebilizumab for NMOSD
Progressive MS
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Other
WNT9B-gene variant associated with doubled relapse risk in MS
Melatonin associated with improved sleep quality in MS patients
“Expanded Disability Status Scale 0 is not normal”
Personality trait alterations in MS patients
Related Articles
December 20, 2022
Early treatment with DMT effective in paediatric-onset MS
September 10, 2020
Two trials comparing relapsing MS treatments
December 16, 2020
Long-term safety and efficacy of ozanimod in relapsing MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy